Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 19/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12509769 | 0.89 | CFTR (0.68) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL14037972 | 0.89 | CFTR (0.60) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL14038033 | 0.88 | CFTR (0.67) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL2031228 | 0.88 | CFTR (0.56) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL16168279 | 0.88 | CFTR (0.66) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL1723186 | 0.86 | CFTR (0.54) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL1721751 | 0.85 | CFTR (0.57) | CFTR | |
| SCHEMBL14037963 | 0.84 | CFTR (0.56) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL2032993 | 0.84 | CFTR (0.60) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12189058 | 0.84 | CFTR (0.83) | CFTRNR1I2ADORA3CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345685-B2 | Process and crystalline forms of lumacaftor | LAURUS LABS LIMITED (IN) | 2022-05-31 | — | — | US | disclosed |
| US-11345684-B2 | Process and crystalline forms of Lumacaftor | LAURUS LABS LIMITED (IN) | 2022-05-31 | — | — | US | disclosed |
| US-20210061792-A1 | PROCESS AND CRYSTALLINE FORMS OF LUMACAFTOR | LAURUS LABS LTD (IN) | 2021-03-04 | — | — | US | disclosed |
| US-20210053949-A1 | PROCESS AND CRYSTALLINE FORMS OF LUMACAFTOR | LAURUS LABS LTD (IN) | 2021-02-25 | — | — | US | disclosed |
| US-10844048-B2 | Process and crystalline forms of lumacaftor | LAURUS LABS LIMITED (IN) | 2020-11-24 | — | — | US | disclosed |
| EP-3696174-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-2980077-B1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMA (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2018127846-A1 | PROCESS AND CRYSTALLINE FORMS OF LUMACAFTOR | LAURUS LABS LIMITED (IN) | 2018-07-12 | — | — | WO | disclosed |
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| US-7659268-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-09 | — | — | US | disclosed |
| WO-2009123896-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061792-A1 | PROCESS AND CRYSTALLINE FORMS OF LUMACAFTOR | SOST, LSS, PDE6C | CFTR 65/4885NR1I2 2856/4885ADORA3 1524/4885 |
| US-20090246137-A1 | PYRIDYL DERIVATIVES AS CFTR MODULATORS | CFTR, ABCC4, ABCB1 | CFTR 1/4885NR1I2 1062/4885ADORA3 253/4885 |
| US-10844048-B2 | Process and crystalline forms of lumacaftor | SOST, LSS, PDE6C | CFTR 65/4885NR1I2 2856/4885ADORA3 1524/4885 |
| US-11345684-B2 | Process and crystalline forms of Lumacaftor | SOST, LSS, PDE6C | CFTR 65/4885NR1I2 2856/4885ADORA3 1524/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | CFTR 1/4885NR1I2 1234/4885ADORA3 654/4885 |
| US-11345685-B2 | Process and crystalline forms of lumacaftor | SOST, LSS, PDE6C | CFTR 65/4885NR1I2 2856/4885ADORA3 1524/4885 |
| US-20210053949-A1 | PROCESS AND CRYSTALLINE FORMS OF LUMACAFTOR | SOST, LSS, PDE6C | CFTR 65/4885NR1I2 2856/4885ADORA3 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.